- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
USP21 Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP1069a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
USP21 Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | Q9UK80 |
| Clone Names | 2112205 |
| Calculated MW | 62656 Da |
USP21 Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 27005 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP1069a was selected from the N-term region of human USP21. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
USP21 Antibody (N-term) Blocking Peptide - Protein Information | |
| Name USP21 | |
| Synonyms USP23 | |
| Function Deubiquitinates histone H2A, a specific tag for epigenetic transcriptional repression, thereby acting as a coactivator. Deubiquitination of histone H2A releaves the repression of di- and trimethylation of histone H3 at 'Lys-4', resulting in regulation of transcriptional initiation. Regulates gene expression via histone H2A deubiquitination (By similarity) Also capable of removing NEDD8 from NEDD8 conjugates but has no effect on Sentrin-1 conjugates | |
| Cellular Location Cytoplasm. Nucleus. | |
| Tissue Location Highly expressed in heart, pancreas and skeletal muscle. Also expressed in brain, placenta, liver and kidney, and at very low level in lung | |
USP21 Antibody (N-term) Blocking Peptide - Related products
AP1069a: USP21 Antibody (N-term)
AP2041a: USP21 Antibody (Center)
AP2147a: USP21 Antibody (C-term)
RI15650: USP21 predesign siRNA
BP1069a: USP21 Antibody (N-term) Blocking Peptide
BP2041a: USP21 Antibody (Center) Blocking Peptide
USP21 Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
USP21 is a ubiquitin-specific protease, an enzyme that removes ubiquitin from ubiquitinated proteins. The encoded protein belongs to the C19 peptidase family, also known as family 2 of ubiquitin carboxyl-terminal hydrolases. This protein has been reported to be capable of removing NEDD8 from NEDD8 conjugates. Alternatively spliced transcript variants encoding different isoforms have been identified.
REFERENCES
Puente, X.S., et al., Nat. Rev. Genet. 4(7):544-558 (2003).Gong, L., et al., J. Biol. Chem. 275(19):14212-14216 (2000).Hillier, L.D., et al., Genome Res. 6(9):807-828 (1996).Smith, T.S., et al., Biochim. Biophys. Acta 1490 (1-2), 184-188 (2000).
